Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain | 11 | 2023 | 303 | 1.860 |
Why?
|
| Spinal Cord | 12 | 2013 | 137 | 1.820 |
Why?
|
| Analgesics | 12 | 2023 | 111 | 1.780 |
Why?
|
| Neuralgia | 5 | 2020 | 46 | 1.570 |
Why?
|
| Microglia | 9 | 2014 | 67 | 1.440 |
Why?
|
| Cannabinoids | 6 | 2020 | 56 | 1.410 |
Why?
|
| Hyperalgesia | 8 | 2025 | 83 | 1.370 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2022 | 52 | 1.270 |
Why?
|
| Receptor, Cannabinoid, CB2 | 5 | 2012 | 23 | 1.260 |
Why?
|
| Cannabis | 4 | 2024 | 30 | 1.210 |
Why?
|
| Macrophages | 5 | 2019 | 207 | 1.190 |
Why?
|
| Pain, Postoperative | 6 | 2022 | 198 | 1.060 |
Why?
|
| Dual Specificity Phosphatase 6 | 4 | 2014 | 5 | 0.990 |
Why?
|
| Animals | 37 | 2025 | 8197 | 0.960 |
Why?
|
| Clonidine | 4 | 2007 | 64 | 0.930 |
Why?
|
| Health Status Disparities | 1 | 2025 | 128 | 0.820 |
Why?
|
| Rats | 21 | 2022 | 1895 | 0.820 |
Why?
|
| Homosexuality, Male | 1 | 2025 | 115 | 0.800 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 595 | 0.760 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 180 | 0.760 |
Why?
|
| Keratinocytes | 2 | 2019 | 30 | 0.730 |
Why?
|
| Sciatic Neuropathy | 3 | 2007 | 15 | 0.730 |
Why?
|
| Inflammation | 4 | 2019 | 507 | 0.730 |
Why?
|
| Cannabidiol | 1 | 2022 | 9 | 0.730 |
Why?
|
| Astrocytes | 2 | 2014 | 61 | 0.720 |
Why?
|
| Fibroblasts | 2 | 2019 | 119 | 0.700 |
Why?
|
| Skin | 4 | 2022 | 213 | 0.680 |
Why?
|
| Indoles | 5 | 2017 | 65 | 0.670 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 2 | 2012 | 4 | 0.670 |
Why?
|
| Acetaminophen | 4 | 2007 | 19 | 0.640 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2019 | 20 | 0.630 |
Why?
|
| Cytokines | 6 | 2017 | 237 | 0.630 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2022 | 897 | 0.620 |
Why?
|
| Antigens, CD | 2 | 2019 | 95 | 0.610 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 78 | 0.610 |
Why?
|
| HIV Infections | 1 | 2025 | 450 | 0.610 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2013 | 33 | 0.580 |
Why?
|
| Tretinoin | 3 | 2006 | 33 | 0.570 |
Why?
|
| Dual Specificity Phosphatase 1 | 3 | 2012 | 27 | 0.520 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2006 | 43 | 0.520 |
Why?
|
| Calcium-Binding Proteins | 5 | 2010 | 48 | 0.510 |
Why?
|
| Pain Measurement | 10 | 2010 | 340 | 0.490 |
Why?
|
| Nanotechnology | 1 | 2016 | 18 | 0.490 |
Why?
|
| Neuroglia | 4 | 2010 | 30 | 0.490 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 33 | 0.480 |
Why?
|
| Behavior, Animal | 9 | 2012 | 299 | 0.470 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2010 | 43 | 0.460 |
Why?
|
| Rats, Wistar | 9 | 2007 | 111 | 0.450 |
Why?
|
| Gene Expression | 1 | 2016 | 346 | 0.450 |
Why?
|
| Pain Threshold | 5 | 2008 | 93 | 0.450 |
Why?
|
| Humans | 23 | 2025 | 32284 | 0.440 |
Why?
|
| Facility Design and Construction | 1 | 2014 | 1 | 0.440 |
Why?
|
| Animal Husbandry | 1 | 2014 | 8 | 0.430 |
Why?
|
| Zebrafish | 1 | 2014 | 23 | 0.430 |
Why?
|
| Housing, Animal | 1 | 2014 | 23 | 0.430 |
Why?
|
| Male | 24 | 2025 | 19447 | 0.430 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 15 | 0.420 |
Why?
|
| Isoquinolines | 1 | 2013 | 8 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 4 | 2025 | 792 | 0.390 |
Why?
|
| Touch | 2 | 2012 | 32 | 0.380 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 478 | 0.380 |
Why?
|
| Drug Tolerance | 3 | 2010 | 40 | 0.370 |
Why?
|
| Osteoarthritis | 1 | 2013 | 73 | 0.370 |
Why?
|
| Nitrates | 2 | 2007 | 29 | 0.370 |
Why?
|
| Disease Models, Animal | 9 | 2013 | 1081 | 0.370 |
Why?
|
| Phosphorylation | 5 | 2014 | 250 | 0.360 |
Why?
|
| Anesthetics, Dissociative | 1 | 2011 | 4 | 0.350 |
Why?
|
| Ketamine | 1 | 2011 | 20 | 0.350 |
Why?
|
| Cell Movement | 2 | 2009 | 167 | 0.340 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 73 | 0.340 |
Why?
|
| Mice | 6 | 2025 | 2571 | 0.310 |
Why?
|
| Endocannabinoids | 1 | 2010 | 44 | 0.310 |
Why?
|
| Reflex | 3 | 2007 | 20 | 0.300 |
Why?
|
| Sciatic Nerve | 2 | 2006 | 38 | 0.290 |
Why?
|
| Administration, Oral | 3 | 2006 | 200 | 0.290 |
Why?
|
| Oligodendroglia | 1 | 2008 | 5 | 0.280 |
Why?
|
| Depression | 1 | 2011 | 427 | 0.270 |
Why?
|
| Leukocytes | 3 | 2019 | 60 | 0.260 |
Why?
|
| Xanthines | 3 | 2011 | 10 | 0.260 |
Why?
|
| Lipopolysaccharides | 3 | 2017 | 121 | 0.250 |
Why?
|
| Microfilament Proteins | 5 | 2010 | 37 | 0.250 |
Why?
|
| Neuritis | 1 | 2005 | 4 | 0.230 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2005 | 35 | 0.230 |
Why?
|
| Guatemala | 1 | 2025 | 19 | 0.230 |
Why?
|
| Physical Stimulation | 5 | 2006 | 83 | 0.220 |
Why?
|
| Apoptosis | 1 | 2006 | 375 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2019 | 215 | 0.210 |
Why?
|
| Paclitaxel | 2 | 2022 | 57 | 0.210 |
Why?
|
| Community-Based Participatory Research | 1 | 2025 | 114 | 0.210 |
Why?
|
| Inflammation Mediators | 2 | 2016 | 96 | 0.200 |
Why?
|
| Neuralgia, Postherpetic | 2 | 2015 | 6 | 0.200 |
Why?
|
| Marketing | 1 | 2024 | 39 | 0.200 |
Why?
|
| Cell Line | 2 | 2016 | 454 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 716 | 0.190 |
Why?
|
| United States | 4 | 2024 | 4077 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 79 | 0.190 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 242 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2022 | 11 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 60 | 0.180 |
Why?
|
| Time Factors | 5 | 2017 | 2203 | 0.180 |
Why?
|
| Lysophospholipids | 1 | 2022 | 26 | 0.180 |
Why?
|
| California | 1 | 2022 | 61 | 0.180 |
Why?
|
| Rodentia | 1 | 2022 | 9 | 0.180 |
Why?
|
| Animals, Newborn | 2 | 2014 | 136 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 84 | 0.170 |
Why?
|
| Wound Healing | 2 | 2019 | 184 | 0.170 |
Why?
|
| Back Pain | 1 | 2020 | 25 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2019 | 224 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2025 | 727 | 0.160 |
Why?
|
| Morphine | 2 | 2010 | 50 | 0.160 |
Why?
|
| Tibial Nerve | 1 | 2020 | 19 | 0.150 |
Why?
|
| Antibodies, Blocking | 1 | 2019 | 3 | 0.150 |
Why?
|
| Spinal Nerves | 2 | 2012 | 68 | 0.150 |
Why?
|
| Taxoids | 1 | 2020 | 50 | 0.150 |
Why?
|
| Sural Nerve | 1 | 2020 | 25 | 0.150 |
Why?
|
| Organ Culture Techniques | 1 | 2019 | 44 | 0.150 |
Why?
|
| Endoribonucleases | 1 | 2019 | 5 | 0.150 |
Why?
|
| Median Nerve | 1 | 2020 | 50 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 48 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 3 | 2019 | 51 | 0.150 |
Why?
|
| Dinoprostone | 1 | 2019 | 36 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2019 | 839 | 0.150 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2019 | 49 | 0.150 |
Why?
|
| Tachykinins | 1 | 2019 | 5 | 0.140 |
Why?
|
| Administration, Cutaneous | 2 | 2017 | 116 | 0.140 |
Why?
|
| Sensory Receptor Cells | 1 | 2019 | 35 | 0.140 |
Why?
|
| Electric Stimulation | 3 | 2019 | 135 | 0.140 |
Why?
|
| RNA, Messenger | 2 | 2017 | 499 | 0.140 |
Why?
|
| Cyclohexanols | 2 | 2008 | 22 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2020 | 394 | 0.130 |
Why?
|
| Receptors, Opioid | 2 | 2023 | 14 | 0.130 |
Why?
|
| Genes, Reporter | 1 | 2016 | 41 | 0.120 |
Why?
|
| Neurons | 2 | 2013 | 484 | 0.120 |
Why?
|
| Zymosan | 2 | 2007 | 5 | 0.120 |
Why?
|
| Lumbar Vertebrae | 2 | 2019 | 93 | 0.120 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 60 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2010 | 471 | 0.120 |
Why?
|
| Transfection | 1 | 2016 | 204 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2016 | 52 | 0.120 |
Why?
|
| Receptors, Cannabinoid | 1 | 2015 | 33 | 0.110 |
Why?
|
| Diabetic Neuropathies | 1 | 2015 | 28 | 0.110 |
Why?
|
| Cyclooxygenase 1 | 2 | 2006 | 23 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 52 | 0.110 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2015 | 20 | 0.110 |
Why?
|
| Aquaculture | 1 | 2014 | 1 | 0.110 |
Why?
|
| Amines | 1 | 2015 | 23 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2006 | 299 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 122 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 82 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2016 | 458 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2014 | 80 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 411 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 37 | 0.100 |
Why?
|
| Arthritis, Experimental | 1 | 2003 | 2 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 43 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 764 | 0.100 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 251 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 65 | 0.100 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 143 | 0.100 |
Why?
|
| 4-Nitrophenylphosphatase | 1 | 2012 | 1 | 0.090 |
Why?
|
| Phenanthrenes | 1 | 2012 | 3 | 0.090 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 9 | 0.090 |
Why?
|
| Diterpenes | 1 | 2012 | 22 | 0.090 |
Why?
|
| Female | 3 | 2025 | 19953 | 0.090 |
Why?
|
| Narcotics | 2 | 2010 | 32 | 0.090 |
Why?
|
| TRPV Cation Channels | 2 | 2025 | 26 | 0.090 |
Why?
|
| Quality of Life | 1 | 2017 | 970 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 112 | 0.090 |
Why?
|
| Functional Laterality | 2 | 2008 | 64 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2025 | 454 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 248 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2011 | 158 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2017 | 3409 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 68 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 83 | 0.070 |
Why?
|
| Hot Temperature | 2 | 2010 | 81 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 193 | 0.070 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 60 | 0.060 |
Why?
|
| Phenotype | 1 | 2009 | 622 | 0.060 |
Why?
|
| Cyclohexanes | 1 | 2007 | 6 | 0.060 |
Why?
|
| Phenols | 1 | 2007 | 18 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 2006 | 15 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 38 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 25 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 128 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2006 | 76 | 0.060 |
Why?
|
| Burns | 1 | 2007 | 101 | 0.060 |
Why?
|
| Isoindoles | 1 | 2006 | 6 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 636 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2006 | 35 | 0.060 |
Why?
|
| Ligation | 1 | 2006 | 64 | 0.060 |
Why?
|
| Injections | 1 | 2006 | 72 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2005 | 46 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 97 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2005 | 47 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 544 | 0.060 |
Why?
|
| Carrageenan | 1 | 2004 | 3 | 0.050 |
Why?
|
| Bacteria | 1 | 2025 | 54 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 32 | 0.050 |
Why?
|
| Pressure | 1 | 2004 | 69 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 67 | 0.050 |
Why?
|
| Receptors, Opioid, mu | 1 | 2023 | 36 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2004 | 243 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 40 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2022 | 6 | 0.050 |
Why?
|
| Research | 1 | 2003 | 81 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 727 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2002 | 15 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 42 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 28 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 44 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 41 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 38 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 44 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 67 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 82 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 15 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2010 | 4 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2019 | 11 | 0.040 |
Why?
|
| Substance P | 1 | 2019 | 22 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 29 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 203 | 0.040 |
Why?
|
| Ganglia, Spinal | 1 | 2019 | 59 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 555 | 0.030 |
Why?
|
| Obesity | 1 | 2025 | 1111 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 98 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 150 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2006 | 66 | 0.030 |
Why?
|
| Motor Neurons | 1 | 2006 | 50 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1484 | 0.030 |
Why?
|
| Mesocricetus | 1 | 2015 | 5 | 0.030 |
Why?
|
| Ointments | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 51 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 2317 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2015 | 142 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 178 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 312 | 0.030 |
Why?
|
| Chloralose | 1 | 2003 | 1 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 34 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 164 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 47 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 180 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 86 | 0.020 |
Why?
|
| Naloxone | 1 | 2010 | 32 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2010 | 47 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 247 | 0.020 |
Why?
|
| Morpholines | 1 | 2007 | 47 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2007 | 119 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 10258 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 11847 | 0.010 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 8 | 0.010 |
Why?
|
| Caffeine | 1 | 2003 | 28 | 0.010 |
Why?
|
| Steroids | 1 | 2003 | 35 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 65 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 293 | 0.010 |
Why?
|
Romero-Sandoval's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(257)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(20)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_